Cellogen Therapeutics Raises ₹20 Cr for Gene Therapy

Cellogen Therapeutics Secures ₹20 Cr Funding for Gene Therapy Expansion

Biotech startup Cellogen Therapeutics has announced the successful closure of a funding round, securing ₹20 Crore (approximately $2 Million USD) from Kotak Alternate Asset Managers (Kotak Alts). This significant capital infusion is earmarked to propel the company’s efforts in advancing its clinical -T programs, expanding its gene therapy pipeline, and bolstering its Good Manufacturing Practice ()-compliant manufacturing and regulatory capabilities.

Kotak Alts Invests Through Life Sciences Fund I

The investment was facilitated by Kotak Life Sciences Fund I (KLSF-I), a dedicated investment vehicle managed by Kotak Alts. KLSF-I focuses on supporting early- and growth-stage ventures within the life sciences and healthtech sectors. This move underscores Kotak Alts’ strategic interest in innovative healthcare solutions and its commitment to fostering growth in the burgeoning biotechnology landscape.

Cellogen Therapeutics: Pioneering Affordable Cancer Therapies

Founded in 2021 by Dr. Gaurav Kharya and Dr. Tanveer Ahmad, Cellogen Therapeutics is at the forefront of cellular engineering and gene therapy development. The company is dedicated to creating next-generation therapies, particularly utilizing Chimeric Antigen Receptor T (CAR-T) cells, to combat cancers and blood disorders. A key mission of Cellogen Therapeutics is to make life-saving therapies more affordable and accessible, aiming to price its treatments significantly lower than existing options, targeting between $60,000 to $70,000 compared to the current $500,000 to $700,000 cost.

Innovative Bispecific CAR-T Platform for Enhanced Efficacy

At the core of Cellogen Therapeutics’ innovation is its proprietary bispecific, dual-antigen CAR-T therapy platform. Unlike conventional CAR-T therapies that target a single marker on cancer cells, Cellogen’s platform is engineered to identify and attack two distinct markers. This dual-targeting approach is designed to enhance therapeutic efficacy and reduce the probability of cancer relapse, offering a more robust solution for patients battling complex blood disorders and cancers. The company has already secured a patent for this groundbreaking CAR-T platform.

Advancing Clinical Trials and Pipeline Development

Cellogen Therapeutics is actively working towards initiating Phase I human clinical trials, contingent upon receiving the necessary regulatory approvals. These trials are planned in collaboration with CMC Vellore, a renowned medical institution. Beyond its CAR-T programs, the startup is also developing early-stage therapeutic programs aimed at treating beta-thalassemia and sickle cell disease, further diversifying its impact on critical unmet medical needs. This strategic expansion of its pipeline highlights the company’s ambitious growth trajectory.

Strategic Investment Landscape and Sector Growth

Prior to this funding round, Cellogen Therapeutics had already attracted significant investment, with Hyderabad-based pharmaceutical company Natco Pharma acquiring over a 5% stake for ₹15 Crore. The broader investment climate for the biotech sector in India is robust, with the country hosting over 11,000 biotech startups. The government’s focus on fostering innovation, as evidenced by the announcement of the ‘Biopharma SHAKTI’ scheme in the recent Union Budget, signals a supportive environment for the continued growth and development of the biotechnology industry.

Kotak Alts’ Life Sciences Fund Strategy

Kotak Alts’ Life Sciences Fund I marked its first close in January of the previous year at ₹250 Crore (approximately $29 Million USD). The fund has garnered support from a diverse base of investors, including family offices, ultra-high net worth individuals (UHNIs), industry veterans, and other institutions. KLSF-I adopts a comprehensive investment strategy, backing startups across the entire life cycle—early, growth, and late stages—within key areas such as life sciences, medical devices, digital health, consumer wellness, and diagnostics.

Market Context and Future Outlook

The successful funding of Cellogen Therapeutics reflects a broader trend of increasing investment in innovative healthcare solutions within India. The company’s focus on developing more affordable and effective treatments for challenging diseases positions it well within a rapidly evolving market. With advancements in gene therapy and cellular engineering, Cellogen Therapeutics is poised to make a substantial impact on patient care and the accessibility of advanced medical treatments, both domestically and potentially on a global scale.